Customer Stories
Whether you are working with spatial biology, drug discovery and development, or clinical research, our versatile tissue analysis software lets you build the exact analysis algorithms you need to unlock the secrets of your research.
Real-world applications of Visiopharm software
Neurology
NerValence – AI-assisted detection and quantitation of P-SYN
Developed by CND Life Science in close collaboration with Visiopharm, NerValence quantifies phosphorylated α-synuclein (P-SYN) over time.
It is used by CND pathologists to support identifying patients who may be at risk of Parkinson’s disease or other synucleinopathies years before symptoms arise, enabling earlier interventions and more proactive care strategies.
Additionally, it creates novel capabilities for clinical trials by generating insights on neurological markers in cutaneous tissue.
Oncology
Quantitative Nuclear Grading for NPUC
The deep learning-based Visiopharm APP segments nuclei and measures different morphology parameters as well as mitotic figures. It has been applied to 571 TMAs from patients with Noninvasive Papillary Urothelial Carcinoma (NPUC) with low to high graded tumors. Nuclear morphometry and automated mitotic figure counts can be used to objectively differentiate between grades of NPUC.
Dermatology
Reliable evaluation of skin product efficacy – animal free
A self-developed model using human skin explants in culture medium, allows our customer CHANEL a flexible way to accurately quantify skin reactions, completely animal-free. Tailored deep learning apps are employed to measure the skin’s response to new developed skin products. In a recent study, the precise measurement of the reduction of Loricrin and other biomarkers over time is used to prove the efficacy of a new skin lotion.
Oncology
A digitally delivered oral cancer predictor
– powered by Visiopharm analysis
Developed by Proteocyte with Discovery, the tailored Visiopharm APP robustly measures S100A7 expression in oral lesion samples. Validated by Proteocyte as an LDT, the score confidently assesses the progression risk to oral cancer, with a sensitivity and negative predictive value of 96.2%. Proteocyte Co-founder Dr. Ken Pritzker explains how it works in our blog.
Diabetic kidney disease
Quantifying cysts for kidney disease
NovAliX, a CRO, established a PKD1-inducible knockout mouse strain to study the formation of cysts in a PKD1-inducible knockout mouse strain. Using Discovery, they were able to segment different parts of the kidney to accurately and reproducibly quantify cysts, blood vessels, and ultimately, fibrosis.
CRO stories
Challenged with very specific research questions from their customers, CROs need image analysis capabilities, which are fit for the task. With Visiopharm software, they can offer bespoke analysis to answer the complex biological questions from their clients and deliver high quality data to advance scientific pipelines.
